Indication
Autoimmune Pulmonary Alveolar Proteinosis
5 clinical trials
2 products
1 drug
Product
MolgramostimClinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
PlaceboClinical trial
A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis PatientsStatus: Completed, Estimated PCD: 2019-04-19
Clinical trial
An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Status: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
Inhaled GM-CSF Reduces the Need for Whole Lung Lavage and Improves Gas Exchange in Autoimmune PAP PatientsStatus: Completed, Estimated PCD: 2016-06-01
Drug
GM-CSFClinical trial
An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis PatientsStatus: Terminated, Estimated PCD: 2021-01-14